Hepatotoxicidad por metilprednisolona: Reporte de un caso

Victoria Duarte; Ana Taborda; Yesika de León; Jorge Facal

doi:10.29193/RMU.38.2.9

Authors

Victoria Duarte Hospital Maciel, Residente Medicina Interna
Ana Taborda Hospital Maciel, Asistente Clínica Médica. Especialista en Medicina Interna
Yesika de León Hospital Maciel, Asistente Clínica Médica. Especialista en Medicina Interna
Jorge Facal Hospital Maciel, Clínica Médica 1, Profesor. Especialista en Medicina Interna e Infectología

DOI:

https://doi.org/10.29193/RMU.38.2.9

Keywords:

HEPATOTOXICITY, METILPREDNISOLONA, MULTIPLE SCLEROSIS

Abstract

Introduction: drug induced hepatotoxicity and toxicity induced by other agents is a frequent form of liver injury, accounting for larger number of cases than viral
hepatitis in some countries. Presentation may be variable, from an isolated alteration in the liver function test to severe forms of acute fulminant liver failure. The
study presents a case of severe liver injury following a short cycle with high doses of intravenous methylprednisolone.
Clinical case: 45 year-old female patient. Personal history of multiple sclerosis, with relapse 40 days prior to the consultation, treated with intravenous methylprednisolone.
The patient consulted for jaundice with one week of evolution, abdominal pain, vomiting, anorexia, asthenia, and adynamia in the last month. Paraclinical tests find mixed hyperbilirubinemia, increased transaminases and decreased prothrombin time (PT). Viral, autoimmune and metabolic etiology are ruled out and a hypothesis is made for methylprednisolone-induced hepatotoxicity. The latter is confirmed and evolution is favorable, liver enzymogram being normal after three months, the same as the prothrombin time upon the interruption of methylprednisolone therapy.
Discussion: the first step to diagnose hepatotoxicity is excluding other causes of liver injury. Next, the temporal relationship between drug exposure and liver injury needs to be demonstrated. Last, withdrawing the drug is usually accompanied by clinical and tests improvement. A high degree of suspicion is necessary to diagnose this condition. Therapies with high doses of methylprednisolone may cause severe hepatitis, and it is recurrent upon re-exposure to the drug. Patients with autoimmune diseases have greater risks of developing hepatotoxicity, what results in a therapeutic challenge.

References

1) Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137(12):947-54.
2) Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000; 4(1):73-96.
3) Bessone F, Hernandez N, Tagle M, Arrese M, Parana R, Méndez-Sánchez N, et al. Drug-induced liver injury: a management position paper from the Latin American Association for Study of the liver. Ann Hepatol 2021; 24:100321. doi: 10.1016/j.aohep.2021.100321.
4) Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42(6):1364-72.
5) Rivero Fernández M, Riesco JM, Moreira VF, Moreno A, López San Román A, Arranz G, et al. Toxicidad hepática recurrente secundaria a metilprednisolona intravenosa. Rev Esp Enferm Dig 2008; 100(11):720-3.
6) Zoubek ME, Pinazo-Bandera J, Ortega-Alonso A, Hernández N, Crespo J, Contreras F, et al. Liver injury after methylprednisolone pulses: a disputable cause of hepatotoxicity. A case series and literature review. United European Gastroenterol J 2019; 7(6):825-37.
7) Marinó M, Morabito E, Altea MA, Ambrogini E, Oliveri F, Brunetto MR, et al. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves’ ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest 2005; 28(3):280-4.
8) Fernández-Delgado ND, Forrellat Barrios M, Valledor-Tristá R, Lavaut-Sánchez K, Cervera García I. Hemocromatosis hereditaria tipo I: a propósito de cuatro casos confirmados. Rev Cubana Hematol Inmunol Hemoter 2014; 30(1):59-67.
9) León-González MG, Zárate-Sánchez T, Vargas-Trujillo S, Aguilar Martínez E, Martínez-Bistrain A, Palacios-López C, et al. Hemocromatosis. Revisión de la literatura y presentación de un caso ilustrativo. Rev Méd Hosp Gen Méx 2001; 64(4):246-50.
10) European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 2019; 70(6):1222-61. Disponible en: https://www.sciencedirect.com/science/article/pii/S0168827819301291 [Consulta: 12 abril 2021].
11) Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci 2015; 17(1):14. doi: 10.3390/ijms17010014.
12) LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2012. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK547852/ [Consulta: 9 junio 2021].
13) D`Agnolo HM, Drenth JP. High-dose methylprednisolone-induced hepatitis in a patient with multiple sclerosis: a case report and brief review of literature. Neth J Med 2013; 71(4):199-202.
14) Nociti V, Biolato M, De Fino C, Bianco A, Losavio FA, Lucchini M, et al. Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. Brain Behav 2018; 8(6):e00968.
15) Adamec I, Pavlović I, Pavičić T, Ruška B, Habek M. Toxic liver injury after high-dose methylprednisolone in people with multiple sclerosis. Mult Scler Relat Disord 2018; 25(2015):43-5.